Family Firm Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 33.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,633 shares of the company’s stock after selling 1,848 shares during the period. Family Firm Inc.’s holdings in Johnson & Johnson were worth $530,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Johanson Financial Advisors Inc. increased its stake in Johnson & Johnson by 14,438.5% during the 4th quarter. Johanson Financial Advisors Inc. now owns 2,470,520 shares of the company’s stock worth $16,935,000 after buying an additional 2,453,527 shares during the period. M&G Investment Management Ltd. purchased a new stake in Johnson & Johnson during the 4th quarter worth $269,234,000. California Public Employees Retirement System increased its stake in Johnson & Johnson by 16.9% during the 3rd quarter. California Public Employees Retirement System now owns 10,198,888 shares of the company’s stock worth $1,319,532,000 after buying an additional 1,477,454 shares during the period. Assenagon Asset Management S.A. grew its holdings in Johnson & Johnson by 193.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,661,504 shares of the company’s stock worth $214,965,000 after acquiring an additional 1,094,696 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI grew its holdings in Johnson & Johnson by 129.3% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 1,033,876 shares of the company’s stock worth $133,763,000 after acquiring an additional 583,023 shares in the last quarter. 67.38% of the stock is currently owned by institutional investors and hedge funds.
In other news, COO Michael E. Sneed sold 58,128 shares of Johnson & Johnson stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $149.39, for a total value of $8,683,741.92. Following the completion of the transaction, the chief operating officer now directly owns 107,511 shares of the company’s stock, valued at approximately $16,061,068.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the completion of the transaction, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.
Shares of JNJ stock opened at $150.09 on Friday. The firm has a market cap of $399.68 billion, a P/E ratio of 22.14, a P/E/G ratio of 2.53 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. Johnson & Johnson has a 1-year low of $126.10 and a 1-year high of $154.50. The firm has a fifty day moving average of $148.01 and a two-hundred day moving average of $136.74.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.30%. The company had revenue of $20.75 billion during the quarter, compared to analyst estimates of $20.83 billion. During the same period last year, the business earned $1.97 EPS. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 9.03 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.
Several research analysts have weighed in on JNJ shares. Wells Fargo & Co raised their price objective on shares of Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, January 9th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective for the company in a report on Wednesday, December 18th. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $145.00 to $170.00 in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $161.92.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Balance Sheet
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.